Symbol | Exchange | Currency |
|---|
By Leroy Leo and Mrinalika Roy (Reuters) - Biotech investors nursing losses from stock price falls are now focusing on firms which are closer to getting their drugs to market,...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Consumer Services, Oil & Gas and Consumer Goods sectors led shares higher. At the close in...
Investing.com – U.S. stocks were mixed after the close on Tuesday, as gains in the Utilities, Telecoms and Oil & Gas sectors led shares higher while losses in the Technology,...
Small-cap stocks are companies with market capitalizations of less than $2 billion. These stocks can be very volatile, and thus, could offer impressive returns in the short-term as...
Genocea Biosciences, Inc. (NASDAQ:GNCA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical...
“Bigger isn’t necessarily better.” At present, this holds true for the specialty-pharma sector wherein smaller drugmakers are performing better than their larger...
Genocea Biosciences, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by sequencing of that patient's tumor. Its product candidates include GEN-011 and GEN-009. GEN-011 is an investigational solid tumor cell therapy candidate, which consists of CD4+ and CD8+ neoantigen-targeted peripheral T cells (NPTs) which are specific for up to 30 antigens, designed to limit tumor escape. GEN-011 consists of T cells extracted from the patient’s peripheral blood and specific for ATLAS-prioritized neoantigens. GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The Company is evaluating its Phase I/IIa of GEN-009.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 3.54 | 3.59 | 3.26 | -0.050 | -1.39% | 18.89K | NYSE | |||
| 34.84 | 35.99 | 34.81 | -0.03 | -0.09% | 3.52M | NASDAQ | |||
| 0.008 | 0.01 | 0.0075 | 0.0000 | 0.00% | 0.00 | OTC Markets | |||
| 1.42 | 1.54 | 1.41 | -0.090 | -5.96% | 4.46M | NASDAQ | |||
| 88.56 | 90.66 | 88.53 | -2.48 | -2.72% | 305.56K | OTC Markets | |||
| 18.87 | 19.12 | 18.85 | -0.18 | -0.94% | 105.36K | OTC Markets | |||
| 9.82 | 10.11 | 9.78 | -0.11 | -1.11% | 6.19M | NYSE | |||
| 0.91 | 0.95 | 0.91 | 0.00 | +0.01% | 84.64K | NASDAQ | |||
| 0.71 | 0.82 | 0.45 | +0.327 | +85.33% | 461.78M | NASDAQ | |||
| 48.56 | 50.42 | 48.50 | -1.51 | -3.02% | 1.66M | NYSE | |||
| 6.72 | 6.73 | 6.68 | +0.040 | +0.60% | 48.16K | NYSE | |||
| 17.61 | 17.79 | 17.14 | +0.38 | +2.21% | 4.05M | NYSE | |||
| 3.70 | 3.90 | 3.66 | -0.160 | -4.15% | 9.85M | NASDAQ | |||
| 119.54 | 121.57 | 119.16 | -0.64 | -0.53% | 35.95K | NASDAQ | |||
| 7.20 | 7.20 | 7.20 | +0.150 | +2.13% | 490.00 | OTC Markets |